top left cornertop right corner
Blackburn with Darwen Primary Care Trust - About Us

Medicines Management Board Minutes

The Medicines Management Board meet on a monthly basis to discuss and make decisions on new medicines and policies.


The upcoming dates for 2014/2015 are:


  • Wednesday 16th Dec 2015

  • Wednesday 20th Jan 2016

  • February - no meeting

  • Wednesday 16th March 2016

  • Wednesday 20th April 2016

  • Wednesday 18th May 2016

  • Wednesday 15th June 2016

  • Wednesday 20th July 2016

  • Wednesday 17th August 2016

  • Wednesday 21st September 2016

  • Wednesday 19th October 2016

  • Wednesday 16th November 2016

  • Wednesday 21st December 2016


Below you will find the minutes from each of the meetings from January 2010 onwards. The minutes from subsequent meetings will be added as soon as they become available

Medicine Management Board Meeting Minutes

application/pdfMedicines Management Board Minutes December 2016 (171 KB)20/01/2017Download
application/pdfMedicines Management Board Minutes November 2016 (172 KB)20/01/2017Download
application/pdfMedicine Management Board Minutes 19th October 2016 (178 KB)21/11/2016Download
 Colesevalem - familial hypercholesterolaemia - BLACK TF Tapentadol- neuropathic pain in non–palliative care patients and for non-specific pain - BLACK TF Psoriasis Biologics Pathway - updated with biosimilars included and flexs outside of NICE. E-cigarettes Position Statement - BLACK TRaffic Light Sodium Benzoate - switched to RED Traffic light, Metolazone - remains RED Traffic Light. NOACs - switched to GREEN Traffic Light. LCFT Quetiapine MR To Quetiapine switching guidelines accepted  
application/pdfMedicines Management Board Minutes September 2016 (189 KB)01/11/2016Download
 Methoxyflurane (Penthrox) - RED Traffic Light. Guanfacine - AMBER Traffic Light Insulin Toujeo information leaflet - accepted for use in ELHE - GREEN Traffic Light Neuropathic Pain Patient Information Leaflet - accepted for use in ELHE. Enstilar Foam - added to formulary - GREEN Traffic Light. Cetraben ointment - added to formulary - GREEN Traffic Light. Albiglutide - BLACK Traffic Light Dulaglutide - GREEN Traffic Light Lurasidone- recommendation – for treatment of schizophrenia. For in 
application/pdfMedicines Management Board Minutes 20th July 2016 (177 KB)01/11/2016Download
 Binosto added to formulary with clear indication of patient cohort and place in therapy. AMBER Traffic Light. Accrete®D3 - added to formulary - GREEN Traffic Light. Insulin detemir - GREEN Traffic Light Zero Risk Schemes Position Statement - accepted for use in ELHE Synalar C ®- replace Betnovate C on formulary GREEN Traffic Light. Alogiptin® - Type 2 Diabetes - GREEN Traffic Light Acenocoumarol - nicoumalone - GREEN Traffic Light Pramiprexole MR– generic brand added to formulary - GREEN 
application/pdfMedicine Management Board Minutes June 2016 (181 KB)26/07/2016Download
 Insulin Degludec - AMBER Traffic light. Ulipristal - for treatment of moderate to severe symptoms of Uterine Fibroids in adult women of reproductive age - AMBER Traffic Light. Liothyronine for Refractory Hypothyroidism - BLACK Traffic Light. Liothyronine - secondary and tertiary care for specialist indications as per recommendations - RED Traffic Light. Buprenorphine patch Butec® - replaces Butrans on formulary - AMBER Traffic Light. Sodium chloride 7% nebules Resp-Ease® - replaces Nebusal  
application/pdfMedicines Management Board Minutes May 2016 (179 KB)16/06/2016Download
 NEW PRODUCT REQUESTS: SIMBRINZA® EYE DROPS (brinzolamide & brimonidine combination) - AMBER traffiv light. TIOPEX® EYE DROPS - Timolol 0.1% gel unit doses - AMBER Traffic Light. Sodium Oxybate for narcolepsy with cataplexy -BLACK Traffic Light. Trans-anal Irrigation devices for neurogenic bowel dysfunction AMBER Traffic Light Tadalafil once daily for prostatectomy - BLACK Traffic Light Rheumatoid Arthritis Biologics Pathway updated. Erectile Dysfunction Guideline updated. ELHT Anticoagulan 
application/pdfMedicines Management Board Minutes April 2016 (173 KB)19/05/2016Download
 Wound Care Formulary updated. 1st and 2nd line prescription order forms included. New product request - INDOCYANINE GREEN - assessment of pre-op hepatic function RED traffic light. New product request - ENALAPRIL FOR PAEDIATRICS - AMBER Traffic Light. Formulary changes: Tadalafil once daily - prescribing within sexual health service in specific defined circumstances. RED Traffic Light. Tadalafil once daily - Not recommended for prescribing in primary care or outside of specific defined circu 
application/pdfMedicines Management Board Minutes March 2015 (177 KB)04/05/2016Download
application/pdfMedicines Management Board Minutes January 2016 (177 KB)03/05/2016Download
application/pdfMedicines Management Board Minutes December 2015 (220 KB)03/05/2016Download
application/pdfMedicine Management Board Minutes November 2015 (141 KB)23/12/2015Download
 Triamcinolone Hexacetonide injection approved for use for JIA only in ELHE. Not approved for other indications.Traffic Light: RED for JIA BLACK for other indications Colomycin in non CF Bronchiectesis – is recommended when long term nebulised therapy is being considered. Recommendation accepted for ELHE. Traffic Light: AMBER Magnasparte® - is the first licensed oral magnesium preparation and is the preferred choice for treatment and prevention of magnesium deficiency. Recommendation accepted f 
application/pdfMedicine Management Board Minutes October 2015 (138 KB)23/12/2015Download
 : FORMULARY UPDATES Sucralfate – on-going supply issues, with only unlicensed available, traffic light changed to RED. Intanza – is black traffic light.  
application/pdfMedicines Management Board Minutes September 2015 (182 KB)03/11/2015Download
 Sodium Bicarbonate Oral Solution – include licensed product on formulary. Clear information on dose and length of treatment should be provided to the GP. Traffic light: AMBER ELHT ECZEMA GUIDELINES- agreed in principle. ELHT Guidelines for the Management of Symptoms in the last days/ hours of life approved Naloxegol for treating opioid-induced constipation (TAG 345) - RED Traffic Light. Aflibercept for treating diabetic macular oedema (TAG 346) - RED Traffic Light. Nintedanib for previou 
application/pdfMedicines Management Board Minutes July 2015 (176 KB)24/09/2015Download
 New Product Request – Levofloxacin Eye Drops - RED Traffic Light. NHS England Commissioning Policy statement - Hepatitis C- acknowledged . Dementia Medicines Prescribing Information Sheet – accepted for use in ELHE. Position Statement for JIA in Adults – accepted for use in ELHE. Shared Care Guideline – ADHD in children & adolescents up to age of 18 years accept for use for ELHE. Budesonide - Budenofalk – the Budenofalk brand of budesonide dosing is more flexible than Entocort and it is mor 
application/pdfMedicines Management Board Minutes June 2015 (172 KB)08/09/2015Download
 Eflornithine – red traffic light for licensed indications is acknowledged by dermatology. Lidocaine patches - within licensed indications for Amber traffic light and would not be continued by GP's for unlicensed indications. NICE Recommendations: Rifaximin Amber traffic light agreed for ELHE for NICE indication. Testosterone (Testim) for female sexual dysfunction post oophorectomy or primary ovarian failure - BLACK Traffic Light for ELHE. The Pharmacological Management of Adults with Chron 
application/pdfMedicines Management Board Minutes May 2015 (173 KB)26/06/2015Download
 Insulin Degludec plus Liraglutide (Xultophy) - Traffic Light: BLACK Aciferol D3 2000 units/mL Liquid - GREEN Traffic Light Diclofenac tablets – removed from formulary - BLACK Traffic Light. ELHE GOOD PRACTICE GUIDANCE WHEN REQUIRED MEDICATION IN CARE HOMES. ELHE GOOD PRACTICE GUIDANCE CD'S IN CARE HOMES.  
application/pdfMedicines Management Board Minutes April 2015 (185 KB)25/06/2015Download
 NEW DRUG REQUEST – SECUKINUMAB - Await NICE guidance. NEW DRUG REQUEST – PANCREX V POWDER approved for inclusion in formulary. Olodaterol in the treatment of COPD - Traffic Light: GREY. Nalmefene - Traffic Light: RED Ciprofloxacin eye drops for use in ears - Traffic Light: RED Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrone NICE (TAG 335). Traffic Light: AMBER. Empagliflozin in combination therapy for treating type 2 diabetes as dual therap 
application/pdfMedicine Management Board Minutes Feb 2015 (134 KB)27/04/2015Download
 Sugammadex approved for use by Consultant Anaethetist only. Branded Generics for Oxycodone, Fentanyl patches, Isosorbide mononitrate MR, and mebeverine to be included in formulary Vedolizumab for Crohn's Disease – : BLACK Spironolactone for Acne Vulgaris –Traffic Light: RED SSRI's in Premature Ejaculation (PE) – Traffic Light: Amber Dapoxetine for Premature Ejaculation (PE) – is not recommended due to lack of cost and clinical effective evidence, long-term safety concerns and short-acting nature 
application/pdfMedicine Management Board Minutes Jan 2015 (147 KB)27/04/2015Download
 December 2014 meeting postponed so actions carried forward and discussed Jan 2015 Formulary Updates – Fulvestrant (Faslodex) – Consultant has agreed that patients on Faslodex can be referred to clinic for review. Formulary updates – Mirabegron – awaiting response for guidance on choice of treatment for urinary incontinence for use by Primary care clinicians. Nicardipine approved for use on critical care unit. Lacosamide approved for specialist paediatric use. Traffic light: RED  
application/pdfELHE Medicines Management Board Minutes November 2014 (172 KB)03/02/2015Download
 Lisdexamphetamine- treatment of ADHD in children and adults only in complex patients who meet two specific criteria- RED Traffic Light. Dabrafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma – is recommended as an option by NICE (TAG 321) - RED Traffic Light. Mexiletine - ventricular tachycardia when other licensed treatments have been unsuccessful - approved for specialist cardiology use RED Traffic Light.  
application/pdfMedicines Management Board Minutes October 2014 (177 KB)02/12/2014Download
 Vitamin D Guidleuines - children approved. Brimonidine gel - symptomatic persistent facial erythema of rosacea - BLACK traffic light . Opthalmology Macular pathways - approved. Subcutaneous Tocilzumab - alternative to intravenous tocilizumab providing patient meets the prescribing criteria as set out in NICE technology appraisals for 1st, 2nd & 3rd line use to treat active rheumatoid arthritis and the agreed Lancashire Rheumatology Alliance flex for use as monotherapy - RED traffic light. RA 
application/pdfMedicine Management Board Minutes 17th September 2014 (190 KB)03/11/2014Download
 ELHT Vitamin D Guidelines – Children - approved for use. Rifaximin added to formulary for hepatic encephalopathy, for consultant gastroenterologist use only and a protocol. Traffic light: RED Simeprevir to be included in formulary if NICE approve in January. Pentoxifylline & Vitamin E for osteonecrosis of the jaw approved subject to satisfactory supply arrangements. Osvaren included in formulary for renal use. Traffic Light: AMBER Certolizumab - of adults with ankylosing spondylitis in line 
application/pdfMedicines Management Board Minutes 16th July 2014 (173 KB)07/10/2014Download
 Vesomni (solifenacin 6mg/tamsulosin 400mcg MR) - moderate to severe storage symptoms & voiding symptoms associated with benign prostatic hypoplasia - BLACk traffic light. Lubiprostone - adults with chronic idiopathic constipation - BLACK traffic light. Certolizumab -treatment of adults with active & progressive psoriatic arthritis in line with NICE TA199 - RED Traffic Light. Armour Thyroid - unlicensed product - BLACK traffic light. Canagliflozin - in combination therapy for treatment of typ 
application/pdfMedicine Management Board Minutes 21st May 2014 (179 KB)31/07/2014Download
 NOAC's position Statement - The position statement with a preferred option NOAC will not be pursued and all three will be available for prescribing, with traffic light remaining Amber. NEW PRODUCT REQUESTS – CARBETOCIN and AZARGA EYE DROPS- deferred  
Page: [1] [2]
[ Next » ]
All material in this section is aimed at health professionals, but is information currently held within the public domain.   Members of the public seeking advice on medicine-related matters are encouraged to speak with their GP, pharmacist or nurse, or contact NHS Direct on 0845 46 47.  

Richard Lee, East Lancashire Health Economy New Drugs Pharmacist.


Powered by EasySite™ Content Management System